Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

Share Price is delayed by 15 minutes
Get Live Data
4,664.00    -214.00 (-4.39%)
Bid:
4,682.00
Ask:
4,686.00
Spread: 4.00 (0.085%)
Market Cap: £17.62b
HLMA Live PriceLast checked at - London Stock Exchange

Intraday Halma Share Chart

Trading Update

26 Sep 2024 07:00

RNS Number : 7027F
Halma PLC
26 September 2024
 

 

Halma plc

Trading update

Halma, the global group of life-saving technology companies focused on growing a safer, cleaner and healthier future for everyone, every day, today releases its scheduled trading update ahead of its half year end on 30 September 2024.

 

Further progress in the first half; unchanged guidance for the full year

We have made further progress in the first half of this financial year, in trading conditions which remain varied across our end markets. This reflects the benefits we derive from our Sustainable Growth Model, including the ability of our companies to respond rapidly to changing market conditions, the talent and entrepreneurialism of our people, and the diversity of our portfolio.

 

Our guidance for the full year to March 2025, for good organic constant currency1 revenue growth and an Adjusted EBIT margin2 of around 21%, remains unchanged from that given in our full year 2024 results announcement in June3.

 

In the first half of the year, we expect to deliver good organic constant currency1 revenue growth, supported by Group order intake in the year to date which is ahead of both revenue and the comparable period last year. We expect the Group's Adjusted EBIT margin2 to be modestly higher than in the first half of the prior year, consistent with our guidance for the year as a whole. We also expect to deliver a strong cash performance, enabling substantial investments, both organically and in acquisitions, to further expand our opportunities for growth over the medium to longer term.

 

The appreciation of Sterling is having a negative currency translation effect on the Group's results; we expect this effect to continue in the second half of the year4.

 

Further M&A progress; healthy acquisition pipeline

We made four acquisitions in the first half of this financial year, all in the Safety sector, for a maximum total consideration of approximately £85m. We continue to have a healthy acquisition pipeline across all three sectors.

 

The acquisitions made in the first half of the year were:

· MK Test Systems Limited, a UK-based company which designs and manufactures safety-critical electrical testing technology, for a consideration of £44m in April. MK Test is a standalone company within the Safety sector;

· G.F.E. - Global Fire Equipment, S.A., a Portuguese designer and manufacturer of fire detection and alarm systems, as a bolt-on for the fire safety company, Ampac, in June. The consideration for GFE was €42.5m (approximately £36m);

· Advantronic, a Spanish manufacturer of control panels and distributor of fire alarm systems, which has strong expertise in wireless technology, as a bolt-on for the fire safety company, Orama, in July. The consideration for Advantronic was €2.3m (approximately £2m);

· RemLive, a UK-based provider of electrical safety products, as a bolt-on for the worker safety company Fortress Safety, in July. The consideration for RemLive was £3.5m.

 

We continue to actively manage our portfolio of global businesses to ensure that it delivers strong growth and returns and is aligned with our purpose of growing a safer, cleaner, healthier future for everyone, every day. As reported in our Full Year 2024 results, we made one small disposal in the period, of Hydreka SAS, for approximately £7m, net of disposal costs.

 

Half Year Results

The results for the half year ending 30 September 2024 will be released on Thursday 21 November 2024.

 

For further information, please contact:

Halma plc

Marc Ronchetti, Group Chief Executive +44 (0)1494 721 111

Steve Gunning, Chief Financial Officer

Charles King, Head of Investor Relations +44 (0) 7776 685 948

Clayton Hirst, Director of Corporate Affairs +44 (0) 7384 796 013

MHP

Oliver Hughes / Rachel Farrington / Ollie Hoare +44 (0)20 3128 8100 / +44 (0)7817 458 804 / halma@mhpgroup.com

Notes:

1. Organic constant currency measures exclude the effect of movements in foreign exchange rates on the translation of revenue and profit into Sterling, as well as acquisitions in the year following completion and disposals.

2. Adjusted EBIT is earnings before interest and tax, and before amortisation and impairment of acquired intangible assets, acquisition items, and profit or loss on disposal of businesses. Adjusted EBIT margin is defined as Adjusted EBIT expressed as a percentage of revenue.

3. The following guidance was given in our Full Year 2024 results announcement in June 2024: "We expect to deliver good organic constant currency1 revenue growth in the year ahead, and an Adjusted EBIT margin2 of around 21%, in the middle of our target range."

4. Sterling has strengthened in the year relative to many currencies, including the US Dollar and Euro. If current exchange rates continue throughout the rest of the current financial year, the currency translation impact on the Group's results is expected to be negative. Based on exchange rates of Sterling/US Dollar 1:1.34 and Sterling/Euro 1:1.20, we would expect approximately a £56m negative revenue effect and approximately a £14m negative profit effect in the 2025 financial year, compared to the 2024 financial year, of which approximately 30% would occur in the first half of the financial year.

5. This Trading Update is based upon unaudited management accounts information. Forward-looking statements have been made by the Directors in good faith using information available up until the date that they approved this statement. Forward-looking statements should be regarded with caution because of the inherent uncertainties in economic trends and business risks.

6. A copy of this announcement, together with other information about Halma, may be viewed on its website at www.halma.com.

About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day. Its purpose defines the three broad market areas where it operates:

· Safety - Protecting people's safety and the environment as populations grow, and enhancing worker safety.

· Environment - Addressing the impacts of climate change, pollution and waste, protecting life-critical resources and supporting scientific research.

· Health - Meeting the increasing demand for better healthcare as chronic illness rises, driven by growing and ageing populations and lifestyle changes.

Halma employs over 8,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

Halma has been named as one of Britain's Most Admired Companies for the past six years.

For more information www.halma.com

===================

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFEDATIEFIS
Date   Source Headline
28th May 20267:15 amRNSExecutive Board changes
13th Apr 20267:00 amRNSAcquisition
12th Mar 20267:00 amRNSTrading Update
13th Jan 20269:18 amRNSDirector/PDMR Shareholding
9th Jan 20261:26 pmRNSDirector/PDMR Shareholding
9th Jan 20267:00 amRNSAcquisition
5th Dec 20257:00 amRNSAcquisition
20th Nov 20257:00 amRNSHalf Year Results
1st Oct 20252:00 pmRNSDirector/PDMR Shareholding
26th Sep 202510:19 amRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSTrading Update
26th Aug 20257:00 amRNSAcquisition
24th Jul 20252:15 pmRNSResult of AGM
30th Jun 202511:30 amRNSDirector/PDMR Shareholding
25th Jun 20258:30 amRNSAGM - Revised Form of Proxy
24th Jun 20259:20 amRNSDirector/PDMR Shareholding
20th Jun 20255:15 pmRNSAnnual Financial Report
18th Jun 20254:47 pmRNSDirector/PDMR Shareholding
12th Jun 20257:00 amRNSFull Year Results
16th May 20257:00 amRNSDirectorate Change
28th Mar 20251:10 pmRNSDirector/PDMR Shareholding
21st Mar 20252:00 pmRNSDirectorate Change
13th Mar 20257:00 amRNSTrading Update
28th Feb 20254:29 pmRNSDirector/PDMR Shareholding
14th Jan 20252:05 pmRNSDirector/PDMR Shareholding
8th Jan 20257:00 amRNSAppointment of Chief Financial Officer
28th Nov 202410:04 amRNSDirector/PDMR Shareholding
22nd Nov 20243:30 pmRNSDirector/PDMR Shareholding
22nd Nov 20243:26 pmRNSDirector/PDMR Shareholding
21st Nov 20247:00 amRNSHalf Year Results
18th Nov 20247:00 amRNSAcquisition
6th Nov 20242:34 pmRNSDirector Declaration
2nd Oct 20249:20 amRNSDirector/PDMR Shareholding
26th Sep 20247:00 amRNSTrading Update
24th Sep 20249:45 amRNSDirector/PDMR Shareholding
3rd Sep 20249:15 amRNSPDMR Shareholding
25th Jul 20241:51 pmRNSResult of AGM
24th Jul 20249:15 amRNSDirector/PDMR Shareholding
17th Jul 202412:46 pmRNSDirector Declaration
1st Jul 20249:51 amRNSDirector/PDMR Shareholding
27th Jun 20247:00 amRNSAcquisition
25th Jun 20243:00 pmRNSDirector/PDMR Shareholding
24th Jun 20245:26 pmRNSAnnual Financial Report
13th Jun 20247:00 amRNSFull Year Results
1st May 20247:00 amRNSAcquisition
19th Mar 20243:53 pmRNSDirector/PDMR Shareholding
14th Mar 20247:00 amRNSTrading Update
4th Mar 20247:00 amRNSAcquisition
21st Feb 20244:17 pmRNSDirector/PDMR Shareholding
30th Jan 20247:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.